Assessing the prognostic role of panimmune inflammation in high-grade gliomas
- 14 August 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (3) , 1320-1328
Abstract
Objective High-grade gliomas are aggressive brain tumors with poor prognoses. Understanding the factors that influence their progression is crucial for improving treatment outcomes. This study investigates the prognostic significance of panimmune inflammation in patients diagnosed with high-grade gliomas. Materials–Methods Data from 89 high-grade glioma patients were analysed retrospectively. The Panimmune inflammation Value (PIV) of each patient meeting the eligibility criteria was calculated on the basis of platelet, monocyte, neutrophil, and lymphocyte counts obtained from peripheral blood samples taken on the first day of treatment. PIV is calculated using the following formula: PIV = T × M × N ÷ L. A receiver operating characteristic (ROC) analysis was employed to identify the optimal cut-off value for PIV about progression-free survival (PFS) and overall survival (OS) outcomes. The primary and secondary endpoints were the differences in OS and PFS between the PIV groups. The Kaplan‒Meier method was used for survival analyses. Results The ROC analysis indicated that the optimal PIV threshold was 545.5, which exhibited a significant interaction with PFS and OS outcomes. Patients were subsequently divided into two groups based on their PIV levels: a low PIV (L-PIV) group comprising 45 patients and a high PIV (H-PIV) group comprising 44 patients. A comparative analysis of survival rates indicated that patients with elevated PIV had a shorter median PFS of 4.0 months compared to 8.0 months in the low PIV group (P = 0.797), as well as a reduced median OS of 19.0 months versus not available (NA) in the low PIV group (P = 0.215). Conclusion Our study results did not reveal a statistically significant association between H-PIV measurements and reduced PFS or OS. However, PIV effectively stratified newly diagnosed high-grade glioma patients into two distinct groups with significantly different PFS and OS outcomes.Keywords
This publication has 30 references indexed in Scilit:
- An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant GliomasCurrent Treatment Options in Oncology, 2024
- The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitorTranslational Oncology, 2022
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryNeuro-Oncology, 2021
- The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitorsEuropean Journal of Cancer, 2021
- The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsBritish Journal of Cancer, 2020
- Preoperative neutrophil–lymphocyte ratio correlated with glioma grading and glioblastoma survivalNeurological Research, 2018
- Association of the Extent of Resection With Survival in GlioblastomaJAMA Oncology, 2016
- Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycleBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastomaThe Lancet Oncology, 2014
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005